U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H37N5O2
Molecular Weight 451.6043
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CABERGOLINE

SMILES

[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC

InChI

InChIKey=KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

HIDE SMILES / InChI
Molecular Formula C26H37N5O2
Molecular Weight 451.6043
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/dosage/cabergoline.html http://www.wikidoc.org/index.php/Cabergoline http://www.rxlist.com/dostinex-drug.htm

Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. It is FDA approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Common adverse reactions include constipation, nausea, dizziness, headache and fatigue. Cabergoline should not be administered concurrently with D-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.

CNS Activity

Originator

Approval Year

1996
209
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2662
 1.5 nM [Ki]
Agonist
2662
 0.5 nM [Ki]
Agonist
2662
 1.2 nM [Ki]
Agonist
2662
 0.69 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

1.13581438E12
Primary
Approved
8360
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

1.13581438E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.3 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40.3 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
67 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12952 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1884 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2546 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
68.54 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7884663
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/12844325
unknown, unknown
 CABERGOLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
L-dopa, po(370.6 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
Page: p.18, p.19, p.22
unhealthy, 41.0–73.5
n = 34
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: 41.0–73.5
Sex: M+F
Population Size: 34
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
Page: p.18, p.19, p.22
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
Page: p.18, p.19, p.22
2 mg 1 times / day multiple, oral (min)
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Other AEs: Cardiac valvulopathy...
Other AEs:
Cardiac valvulopathy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.4%)
Nausea (0.9%)
Vomiting (0.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Disc. AE: Pleural effusion, Pulmonary fibrosis...
Other AEs: Cardiac valvulopathy, Pericardial fibrosis...
AEs leading to
discontinuation/dose reduction:
Pleural effusion
Pulmonary fibrosis
Other AEs:
Cardiac valvulopathy
Pericardial fibrosis
Retroperitoneal fibrosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
AEs

AEs

AESignificanceDosePopulation
Cardiac valvulopathy
2 mg 1 times / day multiple, oral (min)
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Nausea 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
Vomiting 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
Headache 1.4%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.9
Cardiac valvulopathy
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Pericardial fibrosis
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Retroperitoneal fibrosis
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Pleural effusion Disc. AE
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Pulmonary fibrosis Disc. AE
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Page: p.4
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1437
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1626
 likely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1709
 yes
yes (co-administration study)
Comment: n healthy male volunteers, the mean of Cmax and AUC of cabergoline increased around 2.7 times by coadministration of clarithromycin.
Page: -
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3286
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3286
ChemicalBook
CB0282495
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0282495
MolPort
MolPort-003-845-557
https://www.molport.com/shop/molecule-link/MolPort-003-845-557
ZINC
ZINC000003800008
http://zinc15.docking.org/substances/ZINC000003800008
eMolecules
2727031
https://www.emolecules.com/cgi-bin/more?vid=2727031
PubMed

PubMed

TitleDatePubMed
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
2000 Dec
Prolactinomas in children and adolescents--consequences in adult life.
2001
[Dostinex - the most effective medicine for inhibition of postpartal lactation].
2001
Clinical data on restless legs syndrome: a dose-finding study with cabergoline.
2001
Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
2001
Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
2001
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
2001
Cabergoline for levodopa-induced complications in Parkinson's disease.
2001
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
2001
Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.
2001 Aug
Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
2001 Aug
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
2001 Feb
Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline.
2001 Feb
Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
2001 Feb
ACTH silent adenoma shrinking under cabergoline.
2001 Jan
Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
2001 Jan
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
2001 Jan
Clusterlike headache as first manifestation of a prolactinoma.
2001 Jul-Aug
Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases.
2001 Mar
Polycystic ovary syndrome and hyperprolactinemia.
2001 Mar
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches.
2001 May 31
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
2001 Nov
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
2001 Nov
Determination of cabergoline by electrospray ionization tandem mass spectrometry: picogram detection via column focusing sample introduction.
2001 Oct 15
[A case of elderly onset Parkinson's disease complicated by dropped head syndrome].
2001 Sep
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
2001 Sep
Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
2001 Sep
Pregnancy termination in the bitch and queen.
2002 Aug
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
2002 Dec
Alopecia induced by dopamine agonists.
2002 Dec 24
Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms?
2002 Jan
Gateways to clinical trials.
2002 Jul-Aug
Dopamine receptor agonists for treating prolactinomas.
2002 Jun
[Novel pharmacologic therapies in acromegaly].
2002 May 12
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
2002 Nov
Effect of cabergoline on thyroid function in hyperprolactinaemia.
2002 Nov
Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.
2002 Nov 30
Pregnancy outcome after cabergoline treatment in early weeks of gestation.
2002 Nov-Dec
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002 Oct
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma.
2002 Oct
A practical synthesis of cabergoline.
2002 Oct 4
Radioimmunoassay of prolactin for the meerkat (Suricata suricatta), a cooperatively breeding carnivore.
2003 Feb 1
[Efficacy of cabergoline in the treatment of macroprolactinoma].
2003 Jan 18
Patents

Patents

BE 888243
1
JP2007131542A
1
JP2007517067A
29
US4526892 A
1

Sample Use Guides

In Vivo Use Guide
The recommended dosage for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Tert-butylhydroperoxide caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM).
Substance Class Chemical
Created
by admin
on Thu Jul 06 21:51:56 UTC 2023
Edited
by admin
on Thu Jul 06 21:51:56 UTC 2023
Record UNII
LL60K9J05T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CABERGOLINE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
FCE-21336
Code English
DOSTINEX
Brand Name English
CABERGOLINE [JAN]
Common Name English
CABERGOLINE [VANDF]
Common Name English
VELACTIS
Brand Name English
CABASER
Brand Name English
Cabergoline [WHO-DD]
Common Name English
CABERGOLINE [USP-RS]
Common Name English
ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-
Systematic Name English
CABERGOLINE [ORANGE BOOK]
Common Name English
FCE 21336
Code English
CABERGOLINE [USAN]
Common Name English
1-[(6-Allylergolin-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
Systematic Name English
CABERGOLINE [EP MONOGRAPH]
Common Name English
cabergoline [INN]
Common Name English
CABERGOLINE [MI]
Common Name English
CABERGOLINE [MART.]
Common Name English
CABERGOLINE [USP MONOGRAPH]
Common Name English
CABERGOLINE [EMA EPAR VETERINARY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
NCI_THESAURUS C38149
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
WHO-VATC QG02CB03
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
WHO-ATC N04BC06
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
NDF-RT N0000007618
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
LIVERTOX 135
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
WHO-VATC QN04BC06
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
NDF-RT N0000175827
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
WHO-ATC G02CB03
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
NDF-RT N0000007618
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS VELACTIS [SUSPENDED]
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL1201087
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
DRUG CENTRAL
460
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
MESH
C047047
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
WIKIPEDIA
CABERGOLINE
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
CAS
81409-90-7
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
IUPHAR
37
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
NCI_THESAURUS
C47428
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
INN
5860
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
SMS_ID
100000092143
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
USAN
II-10
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
EPA CompTox
DTXSID6022719
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
RXCUI
47579
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY RxNorm
CHEBI
3286
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
RS_ITEM_NUM
1084306
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
PUBCHEM
54746
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
LACTMED
Cabergoline
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
EVMPD
SUB06041MIG
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
DRUG BANK
DB00248
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
DAILYMED
LL60K9J05T
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
FDA UNII
LL60K9J05T
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY
MERCK INDEX
M2876
Created by admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
PRIMARY Merck Index
Related Record Type Details
Structure of CABERGOLINE DIPHOSPHATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
Structure of CABERGOLINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of CABERGOLINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
METABOLITE -> PARENT
7% in urine
MINOR
URINE
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
METABOLITE -> PARENT
41% in urine
MAJOR
URINE
Related Record Type Details
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-6-(2-PROPENYL)-ERGOLINE-1,8-DICARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
Structure of N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-6-(2-PROPENYL)-ERGOLINE-1,8-DICARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
IMPURITY -> PARENT
Structure of ERGOLINE-1,8-DICARBOXAMIDE, N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-N8-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CABERGOLINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966